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Abstract
Purpose Oncotype DX (ODX) recurrence score (RS)
breast cancer (BC) assay is costly, and performed in
only *1/3 of estrogen receptor (ER)-positive BC patients
in the USA. We have now developed a user-friendly
nomogram surrogate prediction model for ODX based on a
large dataset from the National Cancer Data Base (NCDB)
to assist in selecting patients for which further ODX testing
may not be necessary and as a surrogate for patients for
which ODX testing is not affordable or available.
Methods Six clinicopathologic variables of 27,719 ODX-
tested ER?/HER2-/lymph node-negative patients with
6–50 mm tumor size captured by the NCDB from 2010 to
2012 were assessed with logistic regression to predict high-
risk or low-risk ODXRS test results with TAILORx-trial
and commercial cut-off values; 12,763 ODX-tested
patients in 2013 were used for external validation. The
predictive accuracy of the regression model was yielded
using a Receiver Operator Characteristic analysis. Model
fit was analyzed by plotting the predicted probabilities
against the actual probabilities. A user-friendly calculator
version of nomograms is available online at the University
of Tennessee Medical Center website (Knoxville, TN).
Results Grade and progesterone receptor status were the
highest predictors of both low-risk and high-risk ODXRS,
followed by age, tumor size, histologic tumor type and
lymph-vascular invasion (C-indexes-.0.85 vs. 0.88 for
TAILORx-trial vs. commercial cut-off values,
respectively).
Conclusion This is the first study of this scale showing
confidently that clinicopathologic variables can be used for
prediction of low-risk or high-risk ODXRS using our
nomogram models. These novel nomograms will be useful
tools to help physicians and patients decide whether further
ODX testing is necessary and are excellent surrogates for
patients for which ODX testing is not affordable or
available.
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Introduction
Oncotype DX (ODX) (Genomic Health, Redwood City,
CA) is a commercially available 21-gene breast cancer
recurrence score assay, which has both prognostic and
predictive value for estrogen receptor-positive (ER?)/hu-
man epidermal growth factor receptor 2-negative (HER2-
)/lymph node-negative breast cancer patients [1]. The ODX
recurrence score predicts benefit of adding adjuvant
chemotherapy to hormonal manipulation [2]. ODX testing
Part of this study was presented at the San Antonio Breast Cancer
Symposium in the poster discussion session (PD7-04) on December 9,
2016.
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is currently endorsed by American Society of Clinical
Oncology (ASCO), the National Comprehensive Cancer
Network (NCCN), and others for routine guideline appli-
cation [3–5].
ODX is costly, a factor which contributes to the test
being performed in only approximately one-third of eligi-
ble breast cancer patients in the United States [6]. It is
estimated that ODX is used in less than 20% of patients in
European countries due to limited access and reimburse-
ment [7]. Disparities of its use in the United States have
recently been published [6, 8–10].
A few recent institution-based studies attempted to
predict the results of ODX test using a limited number of
respective institutions’ patients tested with ODX [11–15].
They correlated the results with certain histopathologic
variables available from pathology reports such as
immunohistochemical expressions of ER and progesterone
receptor (PR), immunohistochemical expression or fluo-
rescence in situ hybridization results for HER2, as well as
tumor grade, and tumor size [11–15]. A majority of the
models also used immunohistochemical expression of Ki-
67 proliferation index in spite of its controversy in routine
testing of breast cancers [16].
The objective of our study is to develop user-friendly
nomograms to be used as surrogate prediction models for a
high-risk or a low-risk ODX recurrence score test results.
The nomogram development is based on the large breast
cancer dataset from the National Cancer Data Base
(NCDB), using six common and readily available clinico-
pathologic variables established in clinical practice as
prognostic and/or predictive. These variables are: age,
tumor size, tumor grade, PR status, lymph-vascular inva-
sion (LVI), and histologic type of breast cancer (four most
common types).
Materials and methods
Patients and pathology variables selection
The methods published by Iasonos et al. [17] were used to
construct nomograms to predict for a high-risk or a low-
risk ODX recurrence score based on the commercial cut-
off recurrence score values (0–17 = low-risk and
31–100 = high-risk) or Trial Assigning IndiviuaLized
Options for Treatment (NCT00310180)-TAILORx clinical
trial (TAILORx-trial) cut-off values (0–10 = low-risk and
26–100 = high-risk). Breast cancer patients tested with
ODX assay from 2010 to 2012 and with results recorded as
a numerical value (0–100) were identified in the NCDB
and served as the study cohort.
The NCDB, a clinical oncology database, acquires data
from cancer registries from more than 1,500 Commission
on Cancer-accredited facilities with estimated capture of
70% of all newly diagnosed malignancies in the United
States [18]. The NCDB de-identified data regarding the
names of patients and institutions prior to the release of the
data files. Since criteria of 45 CFR 46.102 d research were
met, Institutional Review Board approval was not required.
Inclusion criteria for creation of the nomograms were:
(1) female, (2) invasive breast carcinoma, (3) ER positive,
(4) HER2 negative, (5) no regional lymph node metastasis,
and (6) tumor size between 6 mm and 50 mm. Our inclu-
sion criteria are the same as the ones recommended as
eligibility criteria for ODX testing by the newest 2016
ASCO clinical practice guidelines [3]. Patients also were
required to have one of the four most frequent histologic
types of breast carcinoma: invasive ductal, invasive lobu-
lar, invasive ductal and lobular, or invasive ductal carci-
noma mixed with other types. Patients with intermediate
ODX score results were excluded, since guidelines for the
role of adjuvant chemotherapy in this group of patients
remains under investigation in an ongoing prospective
TAILORx clinical trial.
The outcome of interest for the nomograms was the
probability of a high-risk or a low-risk ODX recurrence
score.
Nomogram development and statistical methods
Simultaneous logistic regression models were used to
construct the nomograms. Tumor size and age were con-
sidered continuous variables, tumor grade and histology
were ordinal, and LVI and PR were coded as follows:
0 = absent LVI, 0 = PR-negative; 1 = present LVI,
1 = PR-positive. The outcome variable was also similarly
coded with 0 = low-risk ODX recurrence score as a ref-
erence category and 1 = high-risk ODX recurrence score
as the outcome of interest when predicting for a high-risk
ODX recurrence score. Coded outcome variables were
reversed when predicting for a low-risk ODX recurrence
score. Multicollinearity among the predictor variables was
assessed using the variance inflation factor (VIF). VIF
values at or above 2.5 assumed evidence of multi-
collinearity in a model. Calibration of the model was
checked by plotting the predicted probabilities against the
actual probabilities. Discrimination of the model was
assessed using a receiver operating characteristic (ROC)
curve to yield a concordance index (c-index) with 95%
confidence interval (95% CI).
In order to validate the original model, a second inde-
pendent sample of patients was collected from the NCDB
from breast cancer patients tested with ODX assay in 2013,
and with results recorded as a numerical value (0–100).
The logistic regression model was performed with the same
predictor and outcome variables. Multicollinearity,
52 Breast Cancer Res Treat (2017) 163:51–61
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calibration, and discrimination of the validation model
were assessed using the same methods. The findings of the
original model and the validation model were then
compared.
In order to create a nomogram from the predicted
probabilities, a scoring system from 0 to 100 was created.
To calculate scores based on possessing predictor charac-
teristics, the beta coefficients (b) for each predictor vari-
able were given numerical point values. The predictor
variable with the highest b was assigned 100 points. Then,
each remaining b was ranked, divided by the highest b, and
multiplied by 100 to yield their respective point values. For
age and tumor size, absolute maximum b values were
assigned by multiplying the raw b value by the range for
age or tumor size, respectively. The point values for each
variable in the model were summed and linked to their
respective probabilities of having a high-risk or a low-risk
ODX recurrence score. Larger values denoted a higher
probability of having a high-risk or a low-risk ODX
recurrence score. All statistical analyses were conducted
using SPSS Version 22 (Armonk, NY: IBM Corp.), and
then confirmed in R program (Vienna, Austria) [19–21].
An easy, user-friendly online nomogram calculator was
developed in order to expedite the calculations of the
probability of a low-risk or a high-risk ODX score for each
patient and is available at the University of Tennessee
Medical Center web site: https://gsm.utmck.edu/
nomograms.
Results
The original cohort of patients captured by the NCDB
between 2010 and 2012 consisted of 27,685 ODX-tested
patients when applying commercial cut-off values for a
low-risk or a high-risk recurrence score. The external
validation cohort consisted of 12,763 ODX-tested patients
captured by the NCDB in 2013. Descriptive characteristics
of these patients with six clinicopathologic variables cho-
sen for a nomogram creation are contrasted in Tables 1 and
2. Age, tumor size, and PR were found to be statistically
significantly different when the original cohort was com-
pared to the external validation cohort of patients (\.05).
However, these difference were not considered clinically
significant.
In multivariate logistic regression analysis, age, tumor
size, tumor grade, PR status, LVI, and histologic tumor
type were significantly associated with a low-risk or a high-
risk ODX recurrence score test result (Online Resource
tables A1 through A4). The tumor grade and PR status
showed the highest odds ratios: for example, grade 1 tumor
was 49.42 times more likely to be associated with a low-
risk recurrence score than a grade 3 tumor (95% CI
41.37–59.03, p\ .001, commercial cut-off values); nega-
tive PR was 0.052 times less likely to be associated with a
low-risk recurrence score (95% CI .046–.059, p\ .001;
Table A1). In Appendix online only Tables A1 through A4,
the results of the final logistic regression analysis of six
clinicopathologic variables used for creation of the nomo-
grams are listed including b values.
Four nomograms were developed based on these anal-
yses in the original cohort group (n = 27,685 for com-
mercial ODX cut-off values; n = 15,623 for TAILORx-
trial ODX cut-off values; points assigned for nomograms
shown in Online Resource Tables A5 and A6. There was
no evidence of multicollinearity found in our model. The
overall predictive accuracy of the model (c-index) mea-
sured by the ROC curve was .887 (95% CI .880–.893) for
commercial ODX cut-off recurrence score values and .851
(95% CI .845–.857) for TAILORx-trial cut-off values.
Four nomograms in the external validation group were
developed (n = 12,685 for commercial ODX cut-off val-
ues; n = 7454 for TAILORx-trial ODX cut-off values) and
are shown in Figs. 1, 2, 3, and 4; points assigned for
nomograms are shown in Online Resource Tables A5 and
A6. Source code is presented in Online Resource document
A1. There was no evidence of multicollinearity. The
overall predictive accuracy of the model (c-index) mea-
sured by the ROC curve was .89 (95% CI .88–.90) for
commercial ODX cut-off values and .852 (95% CI .842–
.861) for TAILORx-trial ODX cut-off values.
It was established that from six chosen clinicopathologic
variables, tumor grade and PR status had the highest sig-
nificant impact on predicting a high-risk or a low-risk ODX
recurrence score with either commercial cut-off values or
TAILORx-trial cut-off values, followed by age, histologic
tumor type and tumor size, while LVI had minimal impact
(Figs. 1, 2, 3 and 4 and Online Resource Tables A5 and
A6).
Utilizing the nomograms
Each nomogram (Figs. 1, 2, 3, and 4) consists of nine rows.
For an individual patient, each of the six variables is
assigned point values based on their clinicopathologic
characteristics (topmost scale; see also Online Resource
Tables A5 and A6 for assigned points). A vertical line is
drawn between the variable value and the topmost ‘‘points’’
line. All allotted points for six variables are added, and the
total is found in the ‘‘total points’’ row. A vertical line is
then drawn between the final ‘‘total points’’ row and the
‘‘predicted probability’’ row, assigning the final predicted
probability for a high-risk or a low-risk ODX recurrence
score results for an individual patient.
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Nomograms from the external validation cohort were
used for development of our user-friendly online nomo-
gram calculator in order to expedite the calculations of the
probability of a low-risk or a high-risk ODX score for each
patient (https://gsm.utmck.edu/nomograms).
Discussion
ODX was the most commonly utilized breast cancer
genomic assay in the United States recorded by the NCDB
in the time period 2010–2012: from 202,075 ER?/HER2-
negative/lymph node-negative breast cancer patients,
69,415 (34%) had genomic tests performed with 97% of
tests being ODX. ODX is expensive (the current estimated
cost is *$4000 [22]), a factor which contributes to the test
being performed in only approximately one-third of breast
cancer patients in the USA [6] and in\20% of patients in
European countries [7]. Several recent institution-based
studies performed on a limited number of patients have
used some of the pathologic variables routinely available
from pathology reports in order to predict ODX test results
[11–13, 15, 23–27]. Some of these studies have suggested
that ordering ODX test in certain cases would not signifi-
cantly contribute to clinical management decisions
[11, 15, 27]. However, all of these studies were performed
on a limited number of patients (institution based). A
couple of studies used ‘‘H-score’’ for ER and PR scoring
system [12, 27] which is more prone to interobserver
variability. Kim et al. used a different low-risk and high-
risk scoring system [15] in which a low-risk recurrence
score incorporated TAILORx-trial low and intermediate
recurrence scores (B25), and a high score represented
TAILORx-trial high-risk recurrence score (C26) [28]. The
majority of these studies also used Ki-67 proliferation
index, in spite of the lack of consensus on scoring [16],
which is also recognized by the newest 8th edition of the
American Joint Commission on Cancer (AJCC), which will
be in use from January 2018 [29]. Ki-67 proliferation index
has only ‘‘AJCC Level of Evidence: III’’ in the new AJCC
edition.
Fig. 1 Nomogram to predict for high-risk Oncotype DX (ODX)
score (TAILORx-trial cut-off values 26–100). IDC invasive ductal
carcinoma, ILC invasive lobular carcinoma, IDC ? ILC invasive
ductal and lobular carcinoma, IDC ? others invasive ductal carci-
noma mixed with other types
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We have developed novel, user-friendly nomograms as a
surrogate prediction model for ODX test based on the large
dataset from the NCDB of ODX-tested ER ?/HER2-/-
lymph node-negative breast cancer patients. We used age,
tumor size, tumor grade, PR status, LVI, and the four most
common histologic types of breast cancer for predicting
ODX test results. These six clinicopathologic variables
were established in clinical practice as prognostic and/or
predictive and are available from any pathology report. We
found that tumor grade and PR status carried the highest
predictive value for a low-risk or a high-risk ODX score,
which is concordant with results reported by Gage et al.
[11] in 540 patients gathered from three different institu-
tions. Finding the grade as the highest predictor for ODX
score is not surprising, since the grade was recognized as a
significant predictor of breast cancer prognosis many years
ago by the Nottingham Prognostic Index [30, 31] as well as
the surrogate of proliferation at the St. Gallen Consensus
Conference in 2011 [32]. In addition, high tumor grade and
the 21-gene recurrence score were found as significant
predictors of distant recurrence in the founding study of
ODX test reported by Paik et al. [1].
PR was also a major predictor of a high-risk or a low-
risk ODX recurrence score in our study, confirming recent
observation by Chaudhary et al. in which PR-negative
status was associated with higher ODX scores [14]. Our
study is the first to show the predictive value of histologic
tumor type, age, and tumor size to predict ODX test results.
Older patients were less likely to have a high-risk score;
larger tumors were more likely to have a high-risk score in
our study. These observations were not described in the
original study of 21-multigene assay [1], or in a recently
published study on optimizing the use of gene expression
profiling by Kim et al. [15] perhaps due to the relatively
small number of tested patients in those studies in com-
parison to number of patients in our study. LVI had min-
imal impact on prediction of ODX test results in our model.
Our nomograms can be used for predicting ODX test
results with both TAILORx-trial and commercial cut-off
score models. These nomograms therefore accommodate
Fig. 2 Nomogram to predict for a low-risk Oncotype DX (ODX)
score (TAILORx-trial cut-off values 0–10). IDC invasive ductal
carcinoma, ILC invasive lobular carcinoma, IDC ? ILC invasive
ductal and lobular carcinoma, IDC ? others invasive ductal
carcinoma mixed with other types
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for the differences of ODX scoring results currently in use
and allow the interchangeable use of our nomograms/cal-
culators to the clinician’s preferences. We believe that
these options give our study advantage over other studies
which did not use both commercial and TAILORx-trial
cut-off values [11, 12, 15].
ER and PR positivity in our study was established based
on the ASCO/CAP guidelines as C1% of positive staining
cells [33] (guidelines followed by NCDB registrars). ER
and PR status was recorded as either positive or negative in
the NCDB without associated levels of positivity. While
this could be considered as a weakness of our study, we
believe that it was actually a strength, since it confirmed
the robustness of our prediction model even without use of
additional information such as level of positive expression
or the intensity of immunohistochemical staining of ER
and PR. Another strength of our study is supported by the
large datasets from the National Cancer Data Base. Large
number of patients in both the original and the external
validation cohorts (27,685 and 12,763, respectively) were
used to develop nomograms which had high,
acceptable C-indexes (.85–.89). This is the first study of
this scale showing confidently that clinicopathologic vari-
ables can be used for prediction of low-risk or high-risk
ODXRS using our nomogram models.
In the 8th edition of the American Joint Commission on
Cancer (AJCC), which will be in use beginning of January
2018, hormone receptor-positive/HER2-negative and
lymph node-negative breast cancer patients with a low-risk
recurrence score of multigene breast cancer prognostic
panels, such as ODX, Mammaprint, EndoPredict, PAM 50,
and Breast Cancer Index, have been placed into the same
prognostic category as T1a-T1b N0 M0 tumors, regardless
of T size. This intent together with the newest 2016 ASCO
clinical practice guidelines for use of biomarkers to guide
clinical decisions regarding the use of adjuvant systemic
therapy for women with early-stage invasive breast carci-
noma has embraced the use of genomic prognostic assays
as an ideal way of practicing personalized medicine for
each breast cancer patient. Unfortunately, these tests are
expensive and are not affordable or available for the
majority of the breast cancer patients globally. Therefore,
Fig. 3 Nomogram to predict for high-risk Oncotype DX (ODX) score (commercial cut-off values 31–100). IDC invasive ductal carcinoma, ILC
invasive lobular carcinoma, IDC ? ILC invasive ductal and lobular carcinoma, IDC ? others invasive ductal carcinoma mixed with other types
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our nomograms which predict for a high-risk or a low-risk
ODX recurrence score will be useful tools to assist provi-
ders in selecting patients for which further ODX testing
may or may not be necessary. They also may serve as a
surrogate for patients for which ODX testing is not
affordable or available.
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